Case Studies

Challenge: Our diagnostics consultants were asked to develop an ex-US business development strategy and identify sources of non-dilutive finance for a well-backed, venture capital-funded diagnostics...

Challenge A private equity (PE) investor was looking for a partner to be retained as an observer on the board of a regenerative medicine/advanced wound-healing company.

Challenge A pharma company that specializes in discovering and developing antibiotics asked us to help expand the search for a development partner in some of its drug candidates.

Challenge A biotech company developing a cell-based cancer immunotherapy was engaged in licensing discussions with a number of major pharma companies and needed valuation support.

Challenge A division of a multinational pharma company needed to evaluate a pipeline agreement with an antibody platform technology company. They wished to understand the overall value of the...

Challenge A biotech company needed support with an active partnering process with several major pharma companies.

Challenge A division of a multinational pharma company needed support evaluating a pipeline agreement with a platform technology company. The client wanted to know what the overall value of this...

Challenge A university research team had worked for a number of years on the development of a novel interventional cardiology device. Recent progress had been made with preclinical testing on pigs,...

Challenge A company considering an investment in a new early-stage biosensor technology for the measurement of blood pressure needed due diligence support. The product had a number of potential...

Challenge A venture capital investor needed a reality check on a clinical stage cancer biologic prior to a proposed $10m investment.

Challenge Our client asked us to conduct a risk assessment and due diligence of a small molecule oncology compound that had been identified from a phenotypic screen. The molecule was in a Phase I/II...

Challenge We were commissioned to conduct a comprehensive technical risk assessment and due diligence of a novel preclinical, small molecule, kinase inhibitor.